About Genome Engineering
Genome Engineering enables scientists to make changes to DNA, leading to changes in physical traits, like eye color, and disease risk. These technologies act like scissors, cutting the DNA at a specific spot. Then scientists can remove, add, or replace the DNA where it was cut. Scientists are developing gene therapies - treatments involving genome engineering - to prevent and treat diseases in humans. Genome engineering tools have the potential to help treat diseases with a genomic basis, like cystic fibrosis and diabetes, etc.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
CAGR | 24.7% |
The companies operating in this sector are concentrating more on efficient growth, upgrading operational efficiency and productivity, realizing high safety standards, and focus on maintaining sustainable development. The players are focusing on securing the leading position in this industry. They are uninterruptedly observing for the prospect to reinforce their economic advantage. To meet a high market share, and developing socially responsible business companies are identifying various strategic initiatives such as mergers & acquisitions, new product launch, product enhancement, and others. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Genome Engineering market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Thermo Fisher Scientific (United States), Merck & Co (Germany), Horizon Discovery Limited (United Kingdom), Genscript USA (United States), Sangamo Therapeutics (United States), Integrated DNA Technologies (United States), Lonza Group (Switzerland), New England Biolabs (United States), Origene Technologies (United States) and Transposagen Biopharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Cellecta (United States), Genecopoeia (United States) and Calyxt (United States).
Segmentation Overview
AMA Research has segmented the market of Global Genome Engineering market by Type (Reagents & Consumables, Software & Systems and Services), Application (Cell Line Engineering , Animal Genetic Engineering , Plant Genetic Engineering and Others) and Region.
On the basis of geography, the market of Genome Engineering has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. CRISPR will boost the Genome Engineering market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Biotechnology & Pharmaceutical Companies will boost the Genome Engineering market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Governments Fundings for R&D in Genome Engineering and Increasing Number of Strategic Initiative by Leading Players across the Industry
Market Growth Drivers:
Increasing Development of Novel Technologies in Genome Engineering and Surging Prevalence of Genetic Disorders
Challenges:
Complex Technology and Required High Skilled Researchers
Restraints:
High Cost of Genome Engineering Technologies
Opportunities:
High Demand for Genome Engineering in Personalized Medicine and Growth Potential in Emerging market
Market Leaders and their expansionary development strategies
In December 2021, Editas Medicine and Takeda Pharmaceutical Company partnered to develop and commercialize allogeneic CAR-T cell therapies using Editas' CRISPR genome-editing technology.
Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Genome Engineering Service Providers, Government Regulatory and Research Organizations and End-Use Industries
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.